Биологические особенности трансформации плазматических клеток и лабораторная диагностика множественной миеломы
Диссертация
Множественная миелома — заболевание системы крови, биологической основой которого является накопление трансформированных плазматических клеток и продуцируемого ими патологического белка. Сопутствующие органные нарушения включают деструкцию костной ткани, гиперкальциемию, почечную недостаточность и анемию. Согласно классификации Всемирной Организации Здравоохранения (ВОЗ) 2008 г., множественная… Читать ещё >
Список литературы
- Андреева Н.Е. Иммуноглобулинопатии / Н. Е. Андреева, Е. Б. Чернохвостова.-М.: Медицина, 1985. — 240 с.
- Андреева Н.Е. Множественная миелома: прошлое, настоящее, будущее / Н. Е. Андреева // Гематология и трансфузиология 1998. — № 3. — С.4.
- Бессмельцев С.С. Множественная миелома / С. С. Бессмельцев, К. М. Абдулкадыров. СПб.: Диалект, 2004. — 448 с.
- Волкова М.А. Клиническая онкогематология / М. А. Волкова. М.: Медицина, 2007. — 847−867 с.
- Зуева Е.Е. Иммунная система. Иммунограмма. Рекомендации по назначению и применению в лечебно-диагностическом процессе / Е. Е. Зуева, Е. Б. Русанова, А. В. Куртова, А. П. Рыжак, О. В. Галкина, Д. В. Чередниченко. -СПб.: Триада, 2008. 60 с.
- Лисунов И.А. Иммунологические аспекты множественной миеломы / И. А. Лисунов. Новосибирск: Наука, 2003. — 157 с.
- Луговская С.А. Иммунофенотипирование в диагностике гемобластозов / С. А. Луговская, М. Е. Почтарь, Н. Н. Тупицын.- Тверь: Триада, 2005. -С. 168.
- Римашевская Е. В. Множественная миелома с секрецией иммуноглобулина А: особенности течения, прогноза и ответа на терапию / Е. В. Римашевская, Н. Е. Андреева // Гематология и трансфузиология. 2005. № 4. С. 21−26.
- Ю.Ройт А. Иммунология / А. Ройт, Дж. Брюстофф, Д. Мейл. М.: Мир, 2000. -С.582.
- И.Хайдуков С. В. Избранные вопросы современной проточной цитометрии / С. В. Хайдуков, А. В. Зурочка. — Челябинск: Челябинская государственная медицинская академия, 2007. С. 84.
- Эмануэль B.JI. Лабораторная диагностика заболеваний почек. —2-е изд., исп. и доп. Тверь: Триада, 2006. С. 248.
- Arinkin MI. Die intravitale Untersuchungsmethodik des Knochenmarks / Leipzig: Folia Haemat, 1929. P. 233.
- Awisati G. The role of interferon-alpha in the management of myelomatosis / G. Awisati, F. Mandelli // Hemat. Oncol. Clin N. Amer. -1992. Vol.6. -P. 395 405.
- Bailliere’s clinical hematology. International Practice and research. Multiple Myeloma / Guest ed. Mandelli. London — Philadelphia — Sydney: Baillie Tindall, 1995.
- Bataille R. A cellular model for myeloma cell growth and, maturation based on an intraclonal CD45 expression /R. Bataille, N. Robillard, C. Pellat-Deceunynck, M. Amiot // Immunol. Rev. 2003. — Vol. 194. — P. 105−111.
- Bataille R. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging / R. Bataille, B. Durie, J. Grenier // Brit. J. Haemat. 1983. -№ 3. — Vol.55. -P.439−447.
- Bence Jones H. Chemical Pathology / Bence Jones H. Lancet. — 1847- № 2. — P. 88−92.
- Bence Jones H. On the new substance occurring in the urine of patient with mollities ossium / Bence Jones H. // Philos. Trans. R. Soc. Lond. 1848. -Vol.138. -P.55−62.
- Bettini R. Prognostic value of serum beta2-microglobulin in multiple myeloma / R. Bettini, S. Redaelli, C. Maino, S. Bertuol, C. Costantini, A. Lazzarini, L. Brivio, M. Gorini // Recenti. Prog. Med. 2005. -№ 2. -Vol.96. — P.81−6.
- Le Bricon T. Laboratory identification and measurement of urinary proteins / T. Le Bricon // Ann. Biol. Clin. (Paris). -2002. № 5. — Vol.60. — P.525−40.
- Boccadoro M. Plasma cell disorders: Benign monoclonal gammopathy, solitary plasmocytoma, mlriple myeloma and plasma cell leukemia. Textbook of Malignant Hematology / M. Boccadoro., Eds L. Degos, D. Linch, B. Lowenberg. -Martin Dunitz, 1999. P.609−618.
- DeVita Eds V.T. Cancer: principles and practice of oncology / Eds V.T. DeVita, S. Hellman, S.A. Rosenberg Philadelphia etc.: Lippincott Williams&Wikins, 2001.
- Collette M. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells / M. Collette, G. Descamps, C. Pellat-Deceunynck, R. Bataille, M. Amiot // Eur. Cytokine. Netw. 2007. -№ 3. -Vol.18.-P.120−6.
- Chen-Kiang S. Biology of plasma cells / S. Chen-Kiang // Best. Pract. Res. Clin. Haematol. 2005. — № 18. — P.493−507.
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group // Br. J. Haematol. -2003. -№ 5. Vol.121. -P.749−757.
- DiGiuseppe J.A. Flow cytometric immunophenotyping of plasmacytic neoplasms / J.A. DiGiuseppe // Am. J. Clin. Pathol. 2007. — № 2. — Vol.127. — P. 172−4.
- Dispenzieri A. Multiple myeloma: clinical features and indications for therapy / A. Dispenzieri, Robert A. Kyle // Best practice and research clinical haemotology. — 2005. № 4. — Vol. 18. — P. 553−568.
- Dhodapkar M.V. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation,/ M.V. Dhodapkar, E. Abe, A. Theus et al. // Blood. 1998. — Vol.91. — P.2679−2688.
- Davies F.E. Minimal residual disease monitoring in multiple myeloma / F.E. Davies, A.C. Rawstron, G.J. Morgan // Best Pract. Res. Clin. Haematol. 2002. -№ 1. -Vol. -15. -P. 197−222.
- De Vos J. Microarray-based understanding of normal and malignant plasma cells / J. De Vos, D. Horse, T. Reme et al. // Immunol. Rev. 2006. -Vol.210. -P.86−104.
- Durie B.G. Initial recommendations International Myeloma Working Group / B.G. Durie, R.A. Kyle, A. Belch // A publication of International Myeloma Foundation. -2003.-P.30.
- Jego G. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells / G. Jego // Blood. 1999. — Vol.94. -P.701−712.
- Esparis-Ogando A. Bortezomib is an efficient agent in plasma cell leukemias / A. Esparis-Ogando, A. Alegre, B. Aguado, G. Mateo, N. Gutierrez, J. Blade, D. Schenkein, A. Pandiella, J.F. San Miguel // Int. J. Cancer. 2005. -№ 4. -Vol.114. -P.665−7.
- Eds R. E. Lenbard. Clinical oncology / Lenbard Eds R. E., R. T. Osteen, T. Gansler. American//Cancer Society, 2001.
- Flucke U. Pathology along the liver sinusoids: intrasinusoidal findings / U. Flucke, H.P. Fischer // Pathologe. 2008. — № 1. — Vol.29. — P.27−36.
- Greipp P.R. Multiple Myeloma: significance of plasmablastic subtype in morhological classification / P.R. Greipp, N.M. Raymond, R.A. Kyle, M. O’Fallon // Blood. 1985. — Vol.65. -P.305−10.
- Grabar P. Methode permettant l’etude conjuguee des proprieties electrophoretiques et immunochimiques d’un melange de proteins- application au serum sanguine / P. Grabar, C.A. Williams // Biochim. Biophys. Acta. 1953. — Vol.10. — P.193−194.
- Geffroy-Luseau A. Osteoclasts support the survival of human plasma cells in vitro / A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, C. Pellat-Deceunynck // Int. Immunol. 2008. — № 6. — Vol.20. — P.775−82.
- Greipp P.R. International staging system for multiple myeloma / J. San Miguel,
- B.G. Durie, J.J. Crowley, B. Barlogie, J. Blade, M. Boccadoro, J.A. Child, H. Avet-Loiseau, R.A. Kyle, J.J. Lahuerta, H. Ludwig, G. Morgan, R. Powles, K. Shimizu,
- C. Shustik, P. Sonneveld, P. Tosi, I. Turesson, JJ. Westin // Clin. Oncol. 2005. -№ 15. — Vol.23. -P.3412−20.
- George E.D. Multiple myeloma: recognition and management / E.D. George, R. Sadovsky // Am. Fam. Physician. 1999. — № 7. — Vol.59. — P. 1885−94.
- Hideshima T. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets / T. Hideshima, C. Mitsiades // Nature publishing Group. 2007. — Vol.7. — 585−598.
- Hlif S. Monoclonal gammopathy: natural history studied with a retrospective approach. / S. Hlif, V. Haraldsdottir, I. Olafsson, V. Gudnason // Haematologica. -2007.-Vol.92.-P.l 131−1134.
- Halaycio M.E. Clinical Malignant Hematology / M.E. Halaycio, M.A. Sekeres, B.J. Bolwell // Mc Graw Hill. -.2007. P.1224.
- Ironside P. Clinical value of immunoelectrophoresis in multiple myeloma / P. Ironside // Pathology. 1970. — № 1. — Vol.2. — P.53−60.
- Jean-Luc Harousseau. The role of complete response in multiple myeloma / H. Jean-Luc, M. Attal, H. Avet-Loiseau // Blood. 2009. — Vol. 114. — P.3139−3146.
- Jain M. Familial myeloma and monoclonal gammopathy: a report of eight African American families / M. Jain, J. Ascensao, G. Schechter // P. Am. J. Hematol. -2009. № 1. — Vol.84. — P.34−8.
- Katzmann J. A. Screening Panels for Monoclonal Gammopathies: Time to Change / J. A. Katzmann // Clin. Biochem. Rev. 2009. — Vol.30. — P.105−111.
- Katzel J.A. Multiple myeloma: charging toward a bright future / J.A. Katzel, P. Hari, D.H. Vesole // CA Cancer. J. Clin. 2007. — № 5. — Vol.57. — P.301−18.
- Keren D.F. Strategy to diagnose monoclonal gammopathies in serum: high-resolution electrophoresis, immunofixation, and kappa/lambda quantification / D.F. Keren, J.S. Warren, J. B Lowe // Clin. Chem. 1988. — № 11. -Vol.34. -P.2196−201.
- Keren D.F. Procedures for the evaluation of monoclonal immunoglobulins / D.F. Keren // Arch. Pathol. Lab. Med. 1999. — № 2. -Vol.123. — P.126−32.
- Kanderson К С. Multiple myeloma: new insights and therapeutic approaches / К С. Kanderson, R. A. Kyle, W. S. Dalton, T. Landowski, K. Shain, R. Jove, L. Hazlehurst, J. Berenson // American Society of hematology. Hematology. 2000. -P.147−165.
- Kumar S. CD45 expression by bone marrow plasma cells in MM: clinical and biological correlation / S. Kumar, S.V. Rajkumar, T. Kimlinger et al. // Leukemia. -2005. -№ 8. Vol.19. — P.1466−70.
- Kyle R.A. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma / R.A. Kyle, S. V Rajkumar // Leukemia. 2009. -№ 1. -Vol.23. -P.3−9.
- Kyle R. A. Multiple myeloma / R. A. Kyle, S. V. Rajkumar // Blood. 2008. -Vol. 111.- P.2962−2972.
- Kyle R.A. Review of 1027 patients with newly diagnosed multiple myeloma / R.A. Kyle, M.A. Gertz, Т.Е. Witzig, J.A. Lust, M.Q. Lacy, A. Dispenzieri, R.
- Fonseca, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.E. Plevak, T.M. Therneau, P.R. Greipp // Mayo Clin Proc. 2003. — № 1. — Vol.78. — P.21−33.
- Landgren O. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis / O. Landgren, B.M. Weiss // Leukemia. 2009. — № 10. — Vol.23. -P.1691−7.
- Lin P. Flow cytometric immunophenotyping analysis of 306 cases of multiple myeloma / P. Lin, R. Owens, G. Tricot, C.S. Wilson // Am. J. Clin. Pathol. 2004. — № 4. — Vol. 121.- P.482−8.
- Liu Y.J. Regulation of B-cell commitment to plasma cells or to memory В cells / Y.J. Liu, J. Banchereau // Semin. Immunol. 1997. — Vol.9.P.235−240.
- Lynch H.T. Phenotypic heterogeneity in multiple myeloma families / P. Watson, S. Tarantolo, P.H. Wiernik, B. Quinn-Laquer, Bergsagel Isgur K., L.
- Huiart, 0.1. Olopade, H. Sobol, W. Sanger, D. Hogg, D Weisenburger // J. Clin. Oncol. 2005. — № 4. — Vol.23. — P.685−93.
- Marti G. Overview of monoclonal B-cell lymphcytosis / G. F. Marti, Abbasi // Br. J. ofHaemotol. -2007. Vol. l39. -P.701−708
- Marc S. Raab. Multiple myeloma / Marc S. Raab, Klaus Podar, Iris Breitkreutz, Paul G. Richardson, Kenneth C. Anderson // Lancet. 2009. — Vol.374. — P.324−39.
- Hernandez, L. Palomera, D. Carrera, R. Martinez, J. De la Rubia, A. Martin, J. Blade, J J. Lahuerta, A. Orfao, J.F. San Miguel // Blood. 2008. — № 10. -Vol.112. -P.4017−23.
- Pellat-Deceunynck C. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma / C. Pellat-Deceunynck //Leukemia. 1998. -№ 12.-Vol.12. -P.1977−1982.
- Pellat-Deceunynck C. Normal and malignant human plasma cells: proliferation, differentiation and expansions in relation to CD45 expression / C. Pellat-Deceunynck, R, Bataille // Blood Cells, Molecules, and Disease. 2004. -Vol.32. — P.293−301.
- Potdevin F. Immunofixation in agarose gel for the identification of monoclonal immunoglobulins / F. Potdevin, M. Roncato, F. Drupt, M. Paris, M. Leclerc // Ann. Immunol. (Paris). 1983. -№ 1. — Vol.134. -P.105−23.
- Rajkumar S.V. Bone marrow angiogenesis in patients achieving complete response after stem cells transplantation for multiple myeloma / S.V. Rajkumar // Leukemia. 1999. — № 3. — Vol.13. — P.469−472.
- Rawstron A.C. Immunophenotyping of plasma cells / A.C. Rawstron // Curr. Protoc. Cytom. 2006. — Chapter 6. — Unit 6.23.
- Rawstron A.C. European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders / A.C. Rawstron, A. Orfao, M. Beksac, L. Bezdickova, R.A.
- Renuka L. Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results / L. Renuka, Yueju Li, K. Janatpour, L. Beckett, I. Jialal // Am. J. Clin. Pathol. 2007. — Vol.127. — P.746−751.
- Riccardi A. Changing clinical presentation of multiple myeloma / A. Riccardi // Eur. J. Cancer. 1991. -№ 11. — Vol.27. — P. 1401−1405.
- Richard A. McPherson. Henry’s Clinical Diagnosis and Management by Laboratory Methods / Richard A. McPherson, Matthew R. Pincus. Twenty-first edition. 2007. — Chapter VI. — P.789−974.
- Robillard N. Phenotypic characterization of the human myeloma cell growth fraction / N. Robillard, C. Pellat-Deceunynck, R. Bataille // Blood. 2005. -№ 12. — Vol.105. — P.4845−8.
- Ruiz-Arguelles G.J. Cell surface markers in multiple myeloma / GJ. Ruiz-Argtielles, J.F. San Miguel // Mayo Clin. Proc. 1994. — № 7. — Vol. 69. — P.684−90.
- Rumke C.L. The unreliability of the determination of the blood lymphocyte count / C.L. Rumke // Ned. Tijdschr. Geneeskd. 1985. -№ 11.- Vol.129. — P.493−5.
- San Miguel J.F. Conventional diagnostics in multiple myeloma / J.F. San Miguel, N.C. Gutierrez, G. Mateo, A. Orfao // Eur. J. Cancer. 2006 — № 11. — Vol.42. -P. 1510−9.
- San Miguel J.F. Immunophenotype and DNA cell content in multiple myeloma / J.F. San Miguel // Baillieres Clin. Haematol. 1995. — № 4. — Vol.8. — P.735−59.
- San Miguel J. Individualizing treatment of patients with myeloma in the era of novel agents / J. San Miguel, J.L. Harousseau, D. Joshua, K.C. Anderson // J. Clin. Oncol. 2008. — № 16. — Vol.26. — P.2761−6.
- San Miguel J.F. Prognostic features of multiple myeloma / J.F. San Miguel, R. Garcia-Sanz // Best Pract. Res. Clin. Haematol. 2005. — № 4. — Vol.18. -P.569−83.
- Sarasquete M.E., MRD monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative PCR and flow cytometry / M.E. Sarasquete, R. Garsia-Sanz, D. Gonsalez // Hematologica. -2005. Vol.90. — P. 1365−72.
- Seidel C. Serum syndecan-1: a new independent prognostic marker in multiple myeloma / C. Seidel, A. Sundan, M. Hjorth, I. Turesson, I.M. Dahl, N. Abildgaard, A. Waage, M Borset II Blood. 2000. — № 2. — Vol.95. — P.388−92.
- Shirlyn B. McKenzie. Clinical laboratory hematology / Shirlyn B. McKenzie // Pearson: Prentice Hall. 2003. — P. 956.
- Stephan R. Vavricka. Serum protein electrophoresis: An underused but very useful test / Stephan R. Vavricka, Emanuel Burri, Christoph Beglinger, Lukas Degen, Michael Manz // Digestion. 2009. — Vol.79. — P.203−210.
- Tisellius A. A new apparatus for electrophoretic analisys of colloidal mixtures / A. Tisellius // Trans. Faraday Society. 1937. — Vol.33. — P.524.
- Tisellius A. Electrophoretic study of immune sera and purified antibody preparation / A. Tisellius, E.A. Kabat // Journal of Exp. Medicine. 1939. -Vol.69.-P.l 19−131.
- Tichy M. Laboratory identification of monoclonal immunoglobulin / M. Tichy, V. Maisnar // Vnitr. Lek. 2006. — Vol.52. — Suppl. 2. -P.41−5.
- Vincent R.S. Plasmablastic morphology as an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma*/ R.S. Vincent, R. Fonseca, M.Q. Lacy // J. Clin. Oncol. 1999. — Vol.17. — P.1551−7.
- Wilson A.T. Direct Immunoelectrophoresis / A.T. Wilson // J. Immunology. 1964. — Vol.92. — P.431−434.
- Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype / S. Yaccoby // Clin. Cancer. Res. 2005. № 11.- Vol.21. — P.7599−606.